IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/27/2024 | $37.00 | Outperform | Raymond James |
| 8/12/2024 | $38.00 | Buy | H.C. Wainwright |
| 4/15/2024 | Outperform | William Blair | |
| 4/15/2024 | $32.00 | Outperform | Leerink Partners |
| 4/10/2024 | $34.00 | Buy | Citigroup |
| 3/27/2024 | $28.00 | Overweight | Piper Sandler |
New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 CORXEL and LENZ Therapeutics announced positive topline data from Phase 3 study in China for the treatment of presbyopia Cash, cash equivalents and marketable securities of $217.2 million as of September 30, 2024; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 8:00 a.m. ET SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial
SAN DIEGO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, November 6, 2024 at 8:00 a.m. EST to report its third quarter 2024 financial results and provide a business update. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 7959303. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Inves
Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia Announced positive topline and capstone data from the Phase 3 CLARITY study Strengthened financial position with $30 million private placement from Ridgeback Capital in July 2024 Pro forma cash, cash equivalents and marketable securities, inclusive of the private placement, were $226.2 million as of June 30, 2024; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. ET SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ),
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, August 14, 2024 at 4:30 p.m. ET to report its second quarter 2024 financial results and provide a business update. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company's website for 30 days following the event. About LENZ TherapeuticsLENZ Therapeutics is a late clinical-stage
Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024 Capstone data from Phase 3 CLARITY study to be presented at Key Opinion Leader event planned for June 18, 2024 Completed merger with Graphite Bio and concurrent $53.5 million private placement Cash, cash equivalents and marketable securities of approximately $213.3 million as of March 31, 2024; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. ET SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a la
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 8, 2024 at 4:30 p.m. ET to report its first quarter 2024 financial results and provide a business update. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company's website for 30 days following the event. About LENZ TherapeuticsLENZ Therapeutics is a
– LNZ100 selected as lead candidate – Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours – Rapid onset and long duration shown with 71% of participants achieving three-lines or greater improvement at 30 minutes and 40% at 10 hours – New Drug Application submission anticipated in mid-2024 – Company to host a conference call and webcast today at 8:00 a.m. ET LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced positive topline results from its Phase 3 CLAR
Conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. EST LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that the Company will host a conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. ET to discuss the topline results from its Phase 3 CLARITY study, a group of three multi-center, double-masked, randomized active and vehicle-controlled clinical trials evaluating the efficacy and safety of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
Raymond James initiated coverage of LENZ Therapeutics with a rating of Outperform and set a new price target of $37.00
H.C. Wainwright initiated coverage of LENZ Therapeutics with a rating of Buy and set a new price target of $38.00
William Blair initiated coverage of LENZ Therapeutics with a rating of Outperform
Leerink Partners initiated coverage of LENZ Therapeutics with a rating of Outperform and set a new price target of $32.00
Citigroup initiated coverage of LENZ Therapeutics with a rating of Buy and set a new price target of $34.00
Piper Sandler initiated coverage of LENZ Therapeutics with a rating of Overweight and set a new price target of $28.00
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference (London, UK)Management will participate in one-on-one meetings from Tuesday, November 19th through Thursday, November 21st, 2024. Piper Sandler 36th Annual Healthcare Conference (New York, NY)Management is scheduled to participate in a fireside chat on Tuesday, December 3
New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 CORXEL and LENZ Therapeutics announced positive topline data from Phase 3 study in China for the treatment of presbyopia Cash, cash equivalents and marketable securities of $217.2 million as of September 30, 2024; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 8:00 a.m. ET SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial
SAN DIEGO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, November 6, 2024 at 8:00 a.m. EST to report its third quarter 2024 financial results and provide a business update. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 7959303. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Inves
Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). The difference in efficacy was statistically significant in the LNZ100 treatment group compared to the vehicle group (p<0.0001) Rapid onset and long duration shown with 69% of participants achieving three-lines or greater improvement at 30 minutes and 30% at 10 hours 91% of participants indicated they noticed an improvement in their near vision LNZ100 could potentially be the best-in-class non-invasive treatment for presbyopia SHANGHAI, China and SAN DIEGO, Oct.
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for LNZ100 for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. The FDA noted that it is not planning to h
Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced presentations featuring LNZ100 at multiple upcoming ophthalmology and optometry medical conferences, including Eyecelerator at the 2024 American Academy of Ophthalmology (AAO) Annual Meeting on October 17, 2024 and Academy 2024 Indianapolis, presented by the American Academy of Optometry on November 6–9, 2024. Eyecelerator at AAO 2024 presentationTitle: CLARITY Phase 3 study data of LNZ100 for the treatment of presbyopiaFormat:
SAN DIEGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference (New York, NY)Management will participate in one-on-one meetings on Wednesday, September 4, 2024. Wells Fargo Securities 2024 Healthcare Conference (Boston, MA)Management will participate in one-on-one meetings on Thursday, September 5, 2024. H.C. Wainwright 26th A
Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia Announced positive topline and capstone data from the Phase 3 CLARITY study Strengthened financial position with $30 million private placement from Ridgeback Capital in July 2024 Pro forma cash, cash equivalents and marketable securities, inclusive of the private placement, were $226.2 million as of June 30, 2024; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. ET SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ),
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company has submitted a New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for LNZ100 (an aceclidine-based ophthalmic solution) for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. "The submission of our NDA for LNZ100 is a significant milestone for LENZ and is a testament to the tremendous focus, execution and col
424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)
424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)
10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)
8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)
424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)
424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)
8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)
EFFECT - LENZ Therapeutics, Inc. (0001815776) (Filer)
424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)
S-1 - LENZ Therapeutics, Inc. (0001815776) (Filer)
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st
Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company will host a Key Opinion Leader ("KOL") event on Tuesday, June 18, 2024 at 8:00 a.m. ET. The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectiv
SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)
SC 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)
SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)
Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and has discontinued the program. Skye Bioscience shares tumbled 18.9% to $8.87 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Big Tree Cloud Holdings Limited (NASDAQ:DSY) shares jumped 123% to $4.3001 following the completion of the company’s business combination with Plutonian Acquisition Corp. and amid continued volatility following its Nasdaq debut last week. KWESST Micro Systems Inc. (NASDAQ:KWE) gained 79.8% to $0.7082 after the company was aw
U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Monday. Shares of ICC Holdings, Inc. (NASDAQ:ICCH) rose sharply during Monday's session. Mutual Capital Group announced plans to acquire ICC Holdings, Inc. for $23.50 per share in a $73.8 million transaction. ICC Holdings shares jumped 43% to $22.03 on Monday. Here are some other big stocks recording gains in today’s session. QXO, Inc. (NASDAQ:QXO) climbed 28.6% to $283.00. Opera Limited (NASDAQ:OPRA) shares gained 22% to $16.83. Ivanhoe Electric Inc. (NYSE:IE) rose 18% to $10.74. iLearningEngines, Inc. (NASDAQ:AILE) surged 17.5% to $5.58. Cactus, Inc. (NYSE:WHD) surged 13.6% to $53.19. SEA
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(3.53) per share which missed the analyst consensus estimate of $(0.90) by 292.22 percent. This is a 45.69 percent increase over losses of $(6.50) per share from the same period last year.
Leerink Partners analyst Marc Goodman initiates coverage on LENZ Therapeutics (NASDAQ:LENZ) with a Outperform rating and announces Price Target of $32.
William Blair analyst Tim Lugo initiates coverage on LENZ Therapeutics (NASDAQ:LENZ) with a Outperform rating.
Last week, LENZ Therapeutics Inc (NASDAQ:LENZ) released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101. Lead product candidate LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one line or more in distance visual acuity. Citi analyst writes that with promising Phase 3 results and the completion of the reverse merger with Graphite Bio, LNZ100 appears ready to revolutionize the landscape of presbyopia (age-related near-vision loss) treatment. C
Citigroup analyst Yigal Nochomovitz initiates coverage on LENZ Therapeutics (NASDAQ:LENZ) with a Buy rating and announces Price Target of $34.
On Wednesday, LENZ Therapeutics Inc (NASDAQ:LENZ) released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101. Presbyopia is the gradual loss of the eyes’ ability to focus on nearby objects that impact people over 45 years. Lead product candidate LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one line or more in distance visual acuity. In the vehicle-controlled CLARITY 2 trial, the Day 1 results showed: Rapid onset: 71% and 91% of particip